New key regulator of acquisition of immune tolerance to tumor cells in cancer patients
Researchers of the Chromatin and Disease Group from the Bellvitge Biomedical Research Institute (IDIBELL) in Barcelona have identified a distinctive epigenetic event in immune cells that differentiate in the tumoral microenvironment ...
Oct 3, 2017
0
1